Australian health tech startup Harrison.ai scores $112M Series C

Medical imaging plays a critical role in the early detection of diseases such as cancer, but manual interpretation of scans can be time-consuming. Healthcare professionals are increasingly turning to AI-powered tools for more efficient and accurate diagnostic processes.

Harrison.ai, a startup based in Sydney, Australia, has developed AI-enabled medical diagnostic software for analyzing CT scans, X-rays, and pathology slides. The company recently announced a successful Series C funding round of $112 million to expand its reach in key markets like the U.S., EMEA, and Asia Pacific.

The funding was led by Aware Super, ECP Asset Management, and Horizons Ventures, along with new investors like the National Reconstruction Fund and Ord Minnett. Harrison.ai offers two main products: Annalise.ai for radiology and Franklin.ai for pathology, both aimed at improving diagnostic accuracy and efficiency for healthcare providers.

‘A second pair of eyes’

According to Dr. Aengus Tran, CEO and co-founder of Harrison.ai, their solutions act as a second set of eyes for radiologists and pathologists, helping enhance workflow efficiency and reduce the risk of misdiagnosis. The company’s goal is to address the global shortage of skilled clinicians and meet the growing demand for accurate diagnoses.

Founded in 2018 by brothers Aengus and Dimitry Tran, Harrison.ai aims to leverage AI automation to improve healthcare capacity. With a total funding of $240 million, the company has seen significant growth and expansion in the past few years.

Harrison.ai’s technology has been well-received in the market, with its products operational in over 1,000 healthcare facilities worldwide. The company’s focus on early detection and faster treatment decisions has led to positive outcomes for patients.

In addition to its existing products, Harrison.ai is working on a new Prostate Biopsy offering set to launch in 2025. The company’s commitment to continued innovation and expansion is reflected in its plans to introduce more AI automation across various diagnostic tests.

With a team of 200 employees and a presence in 15 countries, Harrison.ai is poised for further growth and success in the healthcare industry. The company’s advanced AI technology sets it apart from competitors and has gained regulatory clearance in multiple countries.

Competition

While there are other players in the AI medical imaging space, Harrison.ai stands out with its Chest X-ray product that has regulatory clearance in 40 countries for detecting a wide range of findings. The company’s CT Brain product has also received regulatory approval for detecting numerous conditions, showcasing its advanced capabilities.

Research conducted by the Asian Institute for Distance Education has shown that Harrison.ai’s AI technology can help detect lung cancer earlier, potentially leading to earlier diagnoses and improved patient outcomes. The company’s access to extensive datasets and collaboration with specialist doctors have contributed to the success of its AI solutions.

Harrison.ai continues to innovate with the launch of Harrions.rad.1, a radiology-specific vision-language model that enhances diagnostic accuracy and efficiency. The company’s commitment to advancing AI automation in healthcare sets it apart as a leader in the industry.